HTG Molecular Diagnostics Inc, Tucson, a provider of instruments and reagents for molecular profiling applications, has joined the Worldwide Innovative Networking (WIN) consortium in personalized cancer medicine as an official technology partner.
WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies, academic institutions, health plans, and patient advocacy groups. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations.
HTG Molecular’s mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. The capabilities of the HTG Edge system have been expanded to fully automate sample and targeted library preparation for next-generation sequencing.
WIN will use the HTG EdgeSeq system and products for lung cancer research and clinical trial investigations aimed at developing gene expression molecular profiling in vitro diagnostic tests for multiple targeted therapies. HTG EdgeSeq technology will enable WIN members to measure quantitative expression of message (mRNA) and microRNA (miRNA) from very small, challenging sample types such as formalin-fixed, paraffin-embedded (FFPE) tissues and plasma from blood. Automated on the HTG EdgeSeq system, HTG EdgeSeq technology couples HTG’s proprietary nuclease protection chemistry with next-generation sequencing (NGS).
HTG expects its membership in WIN will provide important resources and information for the selection of novel therapies for a series of lung cancer trials, in order to better predict outcomes for lung cancer patients than currently accepted genomic analysis alone.
“We are thrilled to partner with WIN to investigate new assays to better diagnose and treat patients afflicted with lung cancer,” says TJ Johnson, CEO of HTG Molecular.
For additional information, visit HTG Molecular Diagnostics.